IVI in the Media

Maeil Business Newspaper | All music is beautiful in its own way, but Violinist Sang Hee Lee’s music shines a special light

Nature | Six months of COVID vaccines: what 1.7 billion doses have taught scientists

Asian Boss | We Asked Top Vaccine Expert About COVID Vaccine Problems

Bloomberg | Consequences of ‘Huge’ Global Gap in Vaccinations

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health


“It is a matter of time before dengue in Southeast Asia becomes endemic in South Korea”

2016-10-10 07:04

An interview with Dr. In-Kyu Yoon, Director of the Dengue Vaccine Initiative and IVI’s Deputy Director General of Science was recently featured in Dong-A Ilbo, South Korea’s third largest daily newspaper and publisher of Dong-A Science, the top science magazine in the nation. In the interview he talks about the possibility of dengue spreading to South Korea. The interview, which was published in Korean, has been translated into English. Read the original interview here (Korean only): http://news.donga.com/3/all/20151124/74977500/1

"Dengue accounts for 41% of Korean nationals’ infections from overseas; there’s a need for increased awareness about the disease among Korean travelers during winter."
"I hope that Korea uses the winter vacation season as an opportunity to increase public awareness about the risk of dengue."

Dr. In-Kyu Yoon, Director of the Dengue Vaccine Initiative at the International Vaccine Institute (IVI), said in an interview with the Dong-A Ilbo, “Travel to Southeast Asia is popular in South Korea, but public awareness about the risk of dengue fever, which is considered one of the most dangerous diseases in these countries, seems to still be low here,” adding, “It is necessary that Korea proactively increases awareness about the risk of dengue fever, like MERS and Ebola, among the general public as well.”

Dengue is an infectious disease that is endemic in Southeast Asia, India and Africa, and is spread through mosquitoes. Signs and symptoms include headache, fever and muscle pain, and some 50 -100 million infections occur worldwide yearly. Approximately 1 - 2.5% of 500,000 people who are diagnosed with severe dengue die. While the number of deaths is not large relatively speaking, the morbidity of dengue is high. The World Health Organization classified dengue as one of the fastest emerging pandemic-prone viral disease in many parts of the world.

Born in Busan, South Korea, Dr. Yoon immigrated to Canada at the age of five, and studied paleobiology at Yale University. He received his medical degree from New York University School of Medicine. As a doctor specializing in allergy and immunology, he served as Chief of Viral Diseases at the U.S. Armed Forces Research Institute of Medical Sciences, and professor at the Uniformed Services University of the Health Sciences of the U.S.

Dr. Yoon started dengue research in earnest in 2003, when he witnessed dengue outbreaks during duty travel to Thailand while serving in the U.S. military.

“Previously, I had no special interest in dengue, but when I saw patients in fear and suffering at a local hospital, I felt the need to conduct research on dengue,” Dr. Yoon said. “I still have vivid memories of two or three children with dengue using a single bed due to lack of available beds in the hospital.”

Dr. Yoon said, “So far, South Korea does not have a dengue patient that has been infected domestically,” but he predicted, “Considering the discovery of the mosquito vector that is associated with carrying the dengue virus in Jeju Island, and a growing number of people infected overseas, it is a matter of time before dengue becomes endemic here.”

Dr. Yoon said, “So far, South Korea does not have a dengue patient that has been infected domestically,” but he predicted, “Considering the discovery of the mosquito vector that is associated with carrying the dengue virus in Jeju Island, and a growing number of people infected overseas, it is a matter of time before dengue becomes endemic here.”

In fact, according to the South Korean Ministry of Health and Welfare, the disease that infected most Korean nationals overseas over the past five years was dengue. Last year alone, 41 percent (164 people) were dengue patients among the group who contracted infectious diseases abroad.

“Mosquitos that spread dengue are mostly active during daytime, and they lay eggs in clean water, displaying different patterns from other types of mosquitos,” Dr. Yoon said, “Since there are four dengue virus types, even a patient who gets infected once cannot be safe. This also makes development of a vaccine challenging.”

Medical experts predict chances are high that a dengue vaccine will be available on the market in the near future. However, many experts say the development of an affordable vaccine effective for all four virus types will take more time.